- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering | 1 | GlobeNewswire (USA) | ||
| Do | iSpecimen-Aktie fällt nach Preisgestaltung für Kapitalerhöhung | 3 | Investing.com Deutsch | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| Do | iSpecimen stock falls after pricing $4 million public offering | 1 | Investing.com | ||
| Do | iSpecimen announces pricing of $4M underwritten offering | 1 | Seeking Alpha | ||
| Do | iSpecimen prices $4 million public offering at $0.70 per share | 1 | Investing.com | ||
| 10.07. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 27.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 24.06. | iSpecimen gibt Änderungen im Vorstand und neue Direktorenernennung bekannt | 1 | Investing.com Deutsch | ||
| 24.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 10 | SEC Filings | ||
| 05.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | iSpecimen Inc. - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
| 19.05. | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | iSpecimen Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 4 | SEC Filings | ||
| 02.05. | iSpecimen Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 14.04. | iSpecimen Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | iSpecimen Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 11.03. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 94,70 | +1,73 % | 12 Analysts Assess Illumina: What You Need To Know | ||
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? | ||
| INTELLIA THERAPEUTICS | 11,565 | -0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 2,597 | -3,02 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 114,50 | +1,73 % | Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald | ||
| ARROWHEAD PHARMACEUTICALS | 14,100 | +5,15 % | Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics | ||
| GALAPAGOS NV | 28,400 | +2,60 % | Galapagos NV: Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors | New Directors bring deep commercial, operational, and transaction experience to the Board
Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,175 | -6,20 % | Cardiff Oncology vor Entscheidung: Die spannendste Krebs-Aktie! | Es ist der gewohnte Raketenstart nach Maß: Unser neuer Community-Tipp Cardiff Oncology legt furios los, gewinnt allein seit unserer Enthüllung im Live Chat vor genau einer Woche über 20% an Wert. Und... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,300 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| TWIST BIOSCIENCE | 31,390 | +2,41 % | Cathie Wood setzt wieder auf Nvidia, auch TSMC wandert verstärkt ins Portfolio, mit Twist Bioscience wird eine Wette eingegangen und Palantir scheint der Investorin zu heiß geworden | Die Börse wird oft als seriöser und kühler Ort angesehen, doch sind die Handelsplätze längst nicht frei von Emotionen. Auch hier gibt es prominente Investorinnen und Investoren, die teils wie Popsternchen... ► Artikel lesen | |
| REPLIGEN | 103,90 | +0,19 % | Repligen Q2 2025 Earnings Preview | ||
| ROCKET PHARMACEUTICALS | 2,662 | -0,30 % | Rocket Pharmaceuticals cuts headcount, realigns pipeline | ||
| XBIOTECH | 2,420 | -0,82 % | XBiotech beruft Thomas Kündig und Craig Rademaker in den Vorstand | ||
| SPERO THERAPEUTICS | 1,966 | +0,10 % | Sports Injuries Made Every Day a Mortal Struggle Until The Spero Clinic Began Treatment: Kole Jackson's Story | FAYETTEVILLE, ARKANSAS / ACCESS Newswire / July 7, 2025 / With around 30 million children participating in organized sports in the U.S., almost all of them will experience some kind of injury while... ► Artikel lesen | |
| PERSONALIS | 5,500 | -1,79 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer |
ISPECIMEN INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.